Results 211 to 220 of about 22,260 (249)

Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration

Scott M. Friedman, Nikolas London, Jan Hamouz, Ágnes Kerényi, András Papp, Tamás Pregun, Vincent Chow, Bianca Bautista, Daidong Wang, Gary Grachev, Janet Franklin   +10 more
openalex   +1 more source

Efficacy of Adaptive Blood Purification for Septic Shock (EABPSS): protocol for a randomised, multicentre, parallel controlled study. [PDF]

BMJ Open
Jia H, Li X, Zheng Y, Cui N, Ronco C, Li W.   +5 more
europepmc   +1 more source

Postoperative mobility is associated with risk of reoperation and increased mortality after hip fracture: a nationwide cohort study of 33,486 patients. [PDF]

Acta Orthop
Jensen SS, Gundtoft PH, Gjertsen JE, Pedersen AB.   +3 more
europepmc   +1 more source

Diseño, implementación y evaluación de un modelo de ABP con y sin scaffolding dirigido a alumnos jóvenes y adultos

, 2017
Ana Zuzuarregui, Ángel Pérez Manso
openalex   +1 more source

Utilização da aprendizagem baseada em problemas (ABP) na educação profissional e tecnológica [PDF]

Marcos Javier Alarcón Gallardo, Eduardo Cardoso Moraes   +1 more
openalex  

ABP Publisher's note

Language and Health
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ABP

2022
Dokumentation og vidensdeling af ankesager (ATP og International Pensionsager), direktørklagesager (International Pensionssager) og specialsager (ATP)
openaire   +1 more source

ABP 980: A Trastuzumab Biosimilar

BioDrugs, 2018
ABP 980 (KANJINTI™) is a biosimilar of the reference anti-HER2 antibody trastuzumab. In the EU, ABP 980 is approved for use in all indications for which reference trastuzumab is approved, including HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.
openaire   +2 more sources